Vol 58, No 2 (2007)
Original paper
Published online: 2007-03-13

open access

Page views 679
Article views/downloads 1500
Get Citation

Connect on Social Media

Connect on Social Media

Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report

Beata Kos-Kudła, Anna Zemczak, Wanda Foltyn, Bogdan Marek, Janusz Strzelczyk, Aleksandra Telega, Wojciech Zajęcki, Tomasz Legaszewski, Beata Jurecka-Lubieniecka
Endokrynol Pol 2007;58(2):123-129.


Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and is important in monitoring the disease course and NET treatment.
Aim of the study: Usefulness of suppression test of CgA secretion with octreotide in diagnosis and predicting the therapy outcome in NET patients.
Material and methods: The study included 32 patients with NET of gastrointestinal tract, lung and of unknown origin. CgA level in blood plasma on fasting, before and 30, 60, 90 and 120 minutes after subcutaneous administration of 100 μg octreotide, was determined in all patients. The subjects were divided into two subgroups with relation to CgA level and to the results of somatostatin receptor scintigraphy (SRS).
Results: Statistically significant CgA decrease after octreotide administration in all study time points and positive results of SRS were found in the patients with the elevated CgA level. No statistically significant decrease of CgA level after octreotide was found in the group with normal CgA levels. In this group, 13 patients had a negative result of SRS, and somatostatin receptors expression was found in one patient. Tolerance of somatostatin analogs (SSA) therapy was very good.
Conclusions: Octreotide suppression test with CgA level assessment in NET patients is a simple, straightforward examination, providing information on the predicted response to the applied SSA and the data on initial clinical tolerance of those agents. This examination can also be a screening test useful in planning the treatment with SSA in patients with NET.

Article available in PDF format

View PDF Download PDF file